End-of-day quote
Korea S.E.
06:00:00 2024-05-02 pm EDT
5-day change
1st Jan Change
139,600
KRW
+8.55%
+17.51%
+27.49%
Pharma Research Products Co., Ltd's Equity Buyback announced on February 21, 2019, has expired with 129,237 shares, representing 1.37% for KRW 4,992.18 million.
The company expired its plan on February 21, 2020.
PharmaResearch Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-22
CI
PHARMA RESEARCH BIO Co., Ltd. announced that it has received KRW 30 billion in funding from PharmaResearch Co., Ltd.
21-11-25
CI
PHARMA RESEARCH BIO Co., Ltd. announced that it expects to receive KRW 30 billion in funding from PharmaResearch Co., Ltd.
21-11-23
CI
PharmaResearch Co., Ltd. acquired Medicoson Co., Ltd.
21-11-23
CI
PharmaResearch Co., Ltd. announced that it has received KRW 25 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm
21-10-27
CI
PharmaResearch Co., Ltd. announced that it expects to receive KRW 25 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm
21-10-25
CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.
20-02-21
CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.
20-02-21
CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.
20-02-21
CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.
20-02-21
CI
Pharma Research Products Co., Ltd's Equity Buyback announced on February 21, 2019, has expired with 129,237 shares, representing 1.37% for KRW 4,992.18 million.
20-02-20
CI
Pharma Research Products Co., Ltd's Equity Buyback Plan Extended till February 21, 2020.
19-08-20
CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.
19-05-22
CI
Pharma Research Products Co., Ltd announces an Equity Buyback for KRW 5,000 million worth of its shares.
19-02-21
CI
Pharma Research Products Co., Ltd authorizes a Buyback Plan.
19-02-20
CI
Pharma Research Products Co., Ltd cancelled the acquisition of Cleviel filler business segment from Aestura Corporation.
19-01-10
CI
BIOCND Inc. announced that it has received KRW 10 billion in funding from Pharma Research Products Co., Ltd
18-04-02
CI
Pharma Research Products Co., Ltd completed the acquisition of 42.45% stake in BIOCND Inc. from a group of shareholders.
18-03-27
CI
Ace Susung New Technology Fund 3, Dongyu Investment Co., Ltd and Nau Growth Capital PEF fund managed by Nau IB Capital, Investment Arm completed the acquisition of 3.2% stake in Pharma Research Products Co., Ltd from Jung, Sang-Soo.
18-03-25
CI
Pharma Research Products Co., Ltd announced that it has received KRW 24 billion in funding from Nau IB Capital, Investment Arm, Dongyu Investment Co., Ltd, and another investor
18-03-20
CI
Ace Susung New Technology Fund 3, Dongyu Investment Co., Ltd and Nau Growth Capital PEF fund managed by Nau IB Capital, Investment Arm signed a stock definitive agreement to acquire 3.2% in Pharma Research Products Co., Ltd from Jung, Sang-Soo for KRW 16 billion.
18-03-19
CI
Pharma Research Products Co., Ltd announced that it expects to receive KRW 24 billion in funding from Nau IB Capital, Investment Arm, Dongyu Investment Co., Ltd
18-03-11
CI
Promore Pharma AB Regains Rights for PXL01 Manufacturing from PharmaResearch Products Ltd
18-02-15
CI
BIOCND Inc. announced that it expects to receive KRW 10 billion in funding from Pharma Research Products Co., Ltd
18-01-25
CI
Pharma Research Products Co., Ltd entered into a memorandum of understanding to acquire Cleviel filler business segment from Aestura Corporation for KRW 5.1 billion.
18-01-10
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
PharmaResearch Co Ltd, formerly Pharma Research Products Co Ltd, is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company produces and sells regenerated products such as pharmaceuticals, medical devices, and cosmetics. In addition, the Company is involved in the venture investment and real estate leasing. The Company mainly provides its products in domestic market.
More about the company
Last Close Price
139,600
KRW
Average target price
175,000
KRW
Spread / Average Target
+25.36%
Consensus
1st Jan change
Capi.
+27.49% 1.06B -3.79% 88.14B +1.45% 40.51B -15.94% 31.67B +52.66% 24.62B -14.50% 15.65B -14.38% 12.07B -9.12% 11.97B -42.56% 11.61B +4.87% 8.81B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1